Signet Financial Management LLC Sells 20 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Signet Financial Management LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,983 shares of the biopharmaceutical company’s stock after selling 20 shares during the quarter. Signet Financial Management LLC’s holdings in Regeneron Pharmaceuticals were worth $2,091,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of REGN. GAMMA Investing LLC raised its holdings in Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after acquiring an additional 814,713 shares during the period. Nuveen LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $343,764,000. Pacer Advisors Inc. raised its holdings in Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock valued at $258,366,000 after acquiring an additional 390,374 shares during the period. Assenagon Asset Management S.A. raised its holdings in Regeneron Pharmaceuticals by 171.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company’s stock valued at $305,311,000 after acquiring an additional 303,785 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 18.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock worth $724,984,000 after purchasing an additional 174,056 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ:REGN opened at $576.98 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,070.00. The firm has a fifty day moving average of $569.25 and a 200 day moving average of $573.47. The firm has a market capitalization of $61.15 billion, a PE ratio of 14.54, a price-to-earnings-growth ratio of 1.81 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same period in the previous year, the business earned $11.56 earnings per share. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a report on Friday, August 1st. BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a report on Monday, August 4th. Citigroup reaffirmed a “buy” rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Sanford C. Bernstein upped their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Finally, Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.